β-Galactooligosaccharide In Conjunction With Low FODMAP Diet Improves Irritable Bowel Syndrome Symptoms But Reduces Fecal Bifidobacteria
Notes for this study:
||IBS-related quality of life was unaffected.
|Number of Subjects
||18-29, 30-44, 45-64
In this randomized, 3-arm controlled trial, 69 patients with IBS were assigned to a sham diet with placebo supplement (control), low-FODMAP diet with placebo (LFD), or a low-FODMAP diet plus 1.4g/day beta-galactooligosaccharide (a prebiotic) (LFD/B-GOS) for 4 weeks.
Funding issues for this study:
Gastrointestinal symptoms, fecal microbiota, short-chain fatty acids, and urine metabolites were anaylzed.
The low-FODMAP diet reduced Actinobacteria and butyrate. Though the addition of B-GOS to LFD produced greater improvements compared to the control group, B-GOS did not prevent the LFD-associated reduction in Bifidobacterium and did not produce greater results than LFD alone.
One author was supported by a doctoral research grant from Clasado Biosciences Ltd.. Another author received funding from the Almond Board of California and the International Nut and Dried Fruit Council. Another author received income or grants from AbbVie, Allergan, Ferring, Janssen, Napp, Takeda, and Tillotts. Another author consulted for Danone and received research funding from Clasado Biosciences, Danone, Nestec Ltd, the Almond Board of California, and the International Nut and Dried Fruit Council; this author is also the the coinventor of a low-FODMAP diet mobile app along with one other author (who also consulted for Danone and received funding from Clasado Biosciences, Ltd.)